Optinose downgraded to Neutral from Buy at H.C. Wainwright
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2025
0mins
Downgrade of Optinose: H.C. Wainwright has downgraded Optinose from Buy to Neutral with a price target of $9 following the announcement of its acquisition by Paratek Pharmaceuticals.
Acquisition Details: Paratek Pharmaceuticals will acquire Optinose for $9 per share upfront, along with contingent value rights that could add up to $5 per share.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





